Abstract:Obesity-related renal disease is related to caloric excess promoting deleterious cellular responses. However, a full understanding of the molecular mechanisms involved in progressive kidney disease, as well as a therapeutic strategy, is still absent. Fisetin (FIS), as a natural flavonoid, possesses various bioactivities in a number of disease models. However, its role in obesity-associated kidney injury is still unclear and requires elucidation. In our study, an obesity animal model was established using C57BL/6 mice fed with a normal chow diet (NCD) or high fat diet (HFD) for 16 weeks with or without FIS administration (20, 40 or 80 mg kg(-1)). Our results indicated that chronic HFD feeding led to a significant body weight gain in mice compared to the normal control group, accompanied by a marked insulin resistance and glucose intolerance, whereas FIS treatment exerted prominently protective effects. In addition, FIS significantly attenuated HFD-induced histological alterations in renal tissue samples. Moreover, FIS treatment down-regulated expression of kidney injury molecule-1 (KIM-1), and up-regulated nephrin and podocin expression levels in the kidneys of HFD-fed mice, improving their renal dysfunction. After HFD feeding, mice treated with FIS exhibited a decrease in phosphorylated IRS1(Ser307), and an increase in phosphorylated glycogen synthase kinase 1 (IRS1(Tyr608)), AKT, forkhead box protein O1 (FOXO1) and glycogen synthase kinase (GSK)-3. Furthermore, FIS administration markedly restrained the inflammatory response in the kidneys of HFD-challenged mice, as evidenced by the reduced pro-inflammatory cytokines, tumor necrosis factor- (TNF-), interleukin 6 (IL-6), IL-1 and IL-18, which was attributed to the blockage of nuclear factor B (NF-B) signaling. Importantly, FIS-treated obese mice exerted a remarkable decrease in RIP3 expressions in the kidneys compared to obese mice in the absence of FIS, along with an evident reduction in the NOD-like receptor protein 3 (NLRP3), an apoptosis-associated speck-like protein containing a Caspase recruitment domain (ASC) and Caspase-1. The protective effects of FIS against HFD-induced renal injury were verified in vitro using palmitate (PAL)-treated HK2 cells, an immortalized proximal tubule epithelial cell line from the adult human kidney. In summary, our results supported the notion that FIS functions as a promising agent to improve insulin resistance and inflammatory response against metabolic stress-induced renal injury.

Fisetin Represses Oxidative Stress and Mitochondrial Dysfunction in NAFLD Through Suppressing GRP78-mediated Endoplasmic Reticulum (ER) Stress

Fisetin Ameliorates the Inflammation and Oxidative Stress in Lipopolysaccharide-Induced Endometritis

Fisetin suppresses atherosclerosis by inhibiting ferroptosis-related oxidative stress in apolipoprotein E knockout mice

Fisetin Attenuates High Fat Diet-Triggered Hepatic Lipid Accumulation: A Mechanism Involving Liver Inflammation Overload Associated TACE/TNF-α Pathway

Fagopyrum dibotrys extract improves nonalcoholic fatty liver disease via inhibition of lipogenesis and endoplasmic reticulum stress in high-fat diet-fed mice

Fisetin Attenuates Metabolic Dysfunction in Mice Challenged with a High-Fructose Diet.

Fisetin supplementation prevents high fat diet-induced diabetic nephropathy by repressing insulin resistance and RIP3-regulated inflammation.

Fisetin Protects Against High Fat Diet-Induced Nephropathy by Inhibiting Inflammation and Oxidative Stress Via the Blockage of Irhom2/nf-Κb Signaling

Activated TNF-α/RIPK3 signaling is involved in prolonged high fat diet-stimulated hepatic inflammation and lipid accumulation: inhibition by dietary fisetin intervention.

Fisetin Disrupts Mitochondrial Homeostasis Via Superoxide Dismutase 2 Acetylation in Pancreatic Adenocarcinoma.

Oral Flavonoid Fisetin Treatment Protects Against Prolonged High-Fat-diet-induced Cardiac Dysfunction by Regulation of Multicombined Signaling.

Fisetin mitigates hepatic ischemia-reperfusion injury by regulating GSK3β/AMPK/NLRP3 inflammasome pathway

Fatty Acids Promote Fatty Liver Disease Via the Dysregulation of 3-Mercaptopyruvate Sulfurtransferase/hydrogen Sulfide Pathway.

Fagopyrum dibotrys extract alleviates hepatic steatosis and insulin resistance, and alters autophagy and gut microbiota diversity in mouse models of high-fat diet-induced non-alcoholic fatty liver disease

Fisetin Ameliorates Diabetic Nephropathy-Induced Podocyte Injury by Modulating Nrf2/HO-1/GPX4 Signaling Pathway

Fisetin Protects PC12 Cells from Tunicamycin-Mediated Cell Death via Reactive Oxygen Species Scavenging and Modulation of Nrf2-Driven Gene Expression, SIRT1 and MAPK Signaling in PC12 Cells

Dietary Fisetin Supplementation Protects Against Alcohol-Induced Liver Injury in Mice.

Fisetin Attenuates Gastric Mucosal Lesions through Modulating Nuclear Factor-Kappa B and Peroxisome Proliferator-Activated Receptor- in Rats

Fisetin Nanoparticles Protect Against PM2.5 Exposure-Induced Neuroinflammation by Down-Regulation of Astrocytes Activation Related NF-κB Signaling Pathway

Fucoxanthin Attenuates Free Fatty Acid-Induced Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism/Oxidative Stress/Inflammation via the AMPK/Nrf2/TLR4 Signaling Pathway

Fisetin Ameliorates Hepatocyte Lipid Droplet Accumulation Via Targeting the Rhythmic Protein BMAL1 to Regulate Cell Death-Inducing DNA Fragmentation Factor-α-like Effector C-Mediated Lipid Droplet Fusion.